Anti-influenza hyperimmune immunoglobulin enhances fc-functional antibody immunity during human influenza infection

Journal of Infectious Diseases

Volumn 218, Issue 9, 2018, Pages 1383-1393

  Vanderven, Hillary A ^a,b   Wragg, Kathleen ^a   Ana Sosa Batiz, Fernanda ^a   Kristensen, Anne B ^a   Jegaskanda, Sinthujan ^a   Wheatley, Adam K ^a   Wentworth, Deborah ^c   Wines, Bruce D ^d   Hogarth, P Mark ^d   Rockman, Steve ^a,e   Kent, Stephen J ^a,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

^c UNIVERSITY OF MINNESOTA   (United States)

^d BURNET INSTITUTE   (Australia)

^e Seqirus Ltd   (Australia)

^f MONASH UNIVERSITY   (Australia)

Author keywords

ADCC; Fc receptor; immunoglobulin; influenza; passive transfer

Indexed keywords

FC FUNCTIONAL ANTIBODY; FC RECEPTOR; HUMAN IMMUNOGLOBULIN; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; INFLUENZA VIRUS HEMAGGLUTININ; INTRAGAM P; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; NEUTRALIZING ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS STRAIN; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULINS; INFLUENZA, HUMAN; PILOT PROJECTS; RECEPTORS, IGG;

EID: 85061366752     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy328     Document Type: Article

References (40)

1. World Health Organization. Influenza (seasonal). http:// www.who.int/mediacentre/factsheets/fs211/en/. Accessed 5 February 2015.
2. To KK, Zhang AJ, Hung IF, et al. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vaccine Immunol 2012; 19:1012-8.
3. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-56.
4. Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144:464-73.
5. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Metaanalysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
6. INSIGHT FLU005 Pilot Study Writing Group. An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. J Infect Dis 2016; 213:574-8.
7. Knossow M, Gaudier M, Douglas A, et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 2002; 302:294-8.
8. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-73.
9. Sandbulte MR, Westgeest KB, Gao J, et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci U S A 2011; 108:20748-53.
10. Shil P, Chavan S, Cherian S. Molecular basis of antigenic drift in Influenza A/H3N2 strains (1968-2007) in the light of antigen-antibody interactions. Bioinformation 2011; 6:266-70.
11. Ohta R, Torii Y, Imai M, Kimura H, Okada N, Ito Y. Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol Immunol 2011; 55:191-8.
12. O'Brien KB, Morrison TE, Dundore DY, Heise MT, Schultz-Cherry S. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection. PLoS One 2011; 6:e17377.
13. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166:7381-8.
14. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148:785-94.
15. Hashimoto G, Wright PF, Karzon DT. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect Immun 1983; 42:214-8.
16. Vella S, Rocchi G, Resta S, Marcelli M, De Felici A. Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. J Med Virol 1980; 6:203-11.
17. Greenberg SB, Criswell BS, Six HR, Couch RB. Lymphocyte cytotoxicity to influenza virus-infected cells: Response to vaccination and virus infection. Infect Immun 1978; 20:640-5.
18. Jegaskanda S, Job ER, Kramski M, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190:1837-48.
19. Jegaskanda S, Vandenberg K, Laurie KL, et al. Crossreactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J Infect Dis 2014; 210:1811-22.
20. Jegaskanda S, Laurie KL, Amarasena TH, et al. Ageassociated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis 2013; 208:1051-61.
21. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 2016; 126:605-10.
22. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143-51.
23. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 2013; 87:5512-22.
24. Gerentes L, Kessler N, Thomas G, Aymard M. Simultaneous purification of influenza haemagglutinin and neuraminidase proteins by immunochromatography. J Virol Methods 1996; 58:155-65.
25. Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015; 21:1065-70.
26. Kristensen AB, Lay WN, Ana-Sosa-Batiz F, et al. Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine. J Virol 2016; 90:5724-34.
27. Wines BD, Vanderven HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. Dimeric FcγR ectodomains as probes of the Fc receptor function of anti-influenza virus IgG. J Immunol 2016; 197:1507-16.
28. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, et al. What lies beneath: Antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. EBioMedicine 2016; 8:277-90.
29. Jegaskanda S, Luke C, Hickman HD, et al. Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge. J Infect Dis 2016; 214:945-52.
30. Cox JH. HIV-1-specific antibody-dependent cellular cytotoxicity (ADCC). Methods Mol Med 1999; 17:373-81.
31. Vanderven HA, Liu L, Ana-Sosa-Batiz F, et al. Fc functional antibodies in humans with severe H7N9 and seasonal influenza. JCI Insight 2017; 2. doi:10.1172/jci.insight. 92750.
32. Choi WS, Baek JH, Seo YB, et al; Transgovernmental Enterprise for Pandemic Influenza in Korea. Severe influenza treatment guideline. Korean J Intern Med 2014; 29:132-47.
33. Henry Dunand CJ, Leon PE, Huang M, et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 2016; 19:800-13.
34. Leon PE, He W, Mullarkey CE, et al. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proc Natl Acad Sci U S A 2016; 113:E5944-51.
35. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-93.
36. Rockman S, Lowther S, Camuglia S, et al. Intravenous immunoglobulin protects against severe pandemic influenza infection. EBioMedicine 2017; 19:119-27.
37. Ana-Sosa-Batiz F, Vanderven H, Jegaskanda S, et al. Influenza-specific antibody-dependent phagocytosis. PLoS One 2016; 11:e0154461.
38. Jegaskanda S, Co MDT, Cruz J, Subbarao K, Ennis FA, Terajima M. Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal influenza A viruses that are directed toward the nucleoprotein. J Infect Dis 2017; 215:818-23.
39. Terajima M, Co MD, Cruz J, Ennis FA. High antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9 avian influenza A viruses in healthy US adults and older children. J Infect Dis 2015; 212:1052-60.
40. Jegaskanda S, Vanderven HA, Wheatley AK, Kent SJ. Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design. Hum Vaccin Immunother 2017; 13:1-9.